Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
CareDx combines strong momentum with concrete operating catalysts: shares gained 38.6% through August 27, Q2 revenue rose 52%, and EPS of $0.37 beat $0.22 consensus. Finalized Medicare coverage and strong cash generation reinforce the near-term case.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin expansion ⢠Cash surge ⢠Debt reduction CDNA's strong Q2 2026 profitability, liquidity, and deleveraging support its valuation, but the sharp reversal from 2025 losses warrants caution on earnings durability.
Price Behavior
Key Price Behavior Insights: ⢠Above Moving Average ⢠Key Resistance Test ⢠Elevated Volatility Support Level: $48.97â$49.60 Resistance Level: $50.80â$52.36 CDNA is moderately bullish over the last month above $49.00, but a break above $52.36 would strengthen momentum while a drop below $48.97 would signal deterioration amid high volatility.
Sentiment & News
Key News Insights: ⢠Institutional Accumulation ⢠Baron Share Sale ⢠Valuation Risk CareDx drew mixed but constructive attention, with new institutional buying and favorable screens offset by a major shareholder sale and elevated valuation concerns.
AI Summary
CareDx has evolved into a higher-growth, cash-generative transplant diagnostics platform, with Medicare coverage and NavDx offering meaningful upside, but after a sharp rerating investors should only underwrite the story if reimbursement-driven revenue per test, margins, and recurring cash flow remain durableânot Q2's exceptional net income.
Description
CareDx, Inc. develops and commercializes diagnostic tests and software for transplant patients and clinicians, including donor-derived cell-free DNA and gene-expression assays for surveillance of kidney, heart and lung allografts as well as high-resolution HLA typing, chimerism testing and transplant management tools. The company markets its offerings directly and through distributors and maintains licensing arrangements with partners such as Illumina and Cibiltech. Founded in 1998 and headquartered in South San Francisco, CareDx changed its name from XDx in 2014.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 27 | Sep 3 | CDNA | CareDx, Inc | CareDx combines strong momentum with concrete operating catalysts: shares gained 38.6% through August 27, Q2 revenue rose 52%, and EPS of $0.37 beat $0.22 consensus. Finalized Medicare coverage and strong cash generation reinforce the near-term case. | Closed | -4.8% |